Prostate Biopsy for Prostate Cancer
This study is evaluating whether a two-stage consent process is feasible and acceptable for a clinical trial.
See full descriptionAbout the trial for Prostate Cancer
Treatment Groups
This trial involves 2 different treatments. Prostate Biopsy is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
About The Treatment
Eligibility
This trial is for male patients of any age. There are 2 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Prostate Biopsy will improve 1 primary outcome in patients with Prostate Cancer. Measurement will happen over the course of 2 years.
Patient Q & A Section
How many people get prostate cancer a year in the United States?
Over 230,000 men die from [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) each year in the United States. theme: prostate cancer question: Is tachyphylaxis of osteolytic bone metastases in prostate cancer patients predictable by bone scintigraphy before radiotherapy? answer: Bone scintigraphy before radiotherapy of patients with osteolytic bone metastases allows prediction of bone status before radiotherapy and therefore may help to evaluate the therapy strategy.
What are the signs of prostate cancer?
Patients with unexplained acute urinary retention are at high risk for [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer). Therefore, patients with unexplained acute urinary retention are routinely offered prophylactic biopsy. Prostate specific antigen (PSA) at diagnosis is predictive of the clinical outcome. Biopsy-negative patients with elevated serum PSA levels are managed conservatively as they are predicted to have excellent long-term prognosis.
What causes prostate cancer?
In a cross sectional study of over 6000 men in the Danish national healthcare register, only a small proportion of prostate cancers were attributed to increased exposure to environmental hazards like radiation and air contamination from industrial complexes. We find little evidence relating to other well-defined environmental and demographic agents such as alcohol consumption, type 2 diabetes mellitus, occupation, age, obesity, and use of hormonal medications. However, we found a strong effect of physical exertion per se and a small but noticeable one for education. The association with physical exertion had a weaker and non-significant impact on the observed associations with other common agents or lifestyle factors.
What are common treatments for prostate cancer?
Treatment is tailored depending on the exact circumstances. Common types of prostate cancer are managed with surgery, radiation, hormone replacement therapy, and/or chemotherapy. A combination of these options may be used to treat metastatic disease.
What is prostate cancer?
Prostate cancer (PCa) is a cancer that forms in the prostate and can cause painful sexual intercourse (PSI), frequent or painful urination (PU) or pain during ejaculation (PE). It is the most common form of cancer in adults in Western societies. Prostate cancer is a multi-factorial disease that is caused by a combination of genetic and environmental factors. However, the role of environmental risk factors is still under investigation. It affects about 2.5% of males at some point in their lives. The prostate is a small, gland shaped (organ) structure located below the bladder and attached to the urethra.
What is the average age someone gets prostate cancer?
The average age people get diagnosed with prostate cancer in the United States was 63.2 years. The average age of diagnosis for prostate cancer was 64.9 years, and the average age of death from prostate cancer was 73.3 years, as of 2002. The data for prostate cancer was retrieved from the SEER database (Surgeon General's Surveillance Epidemiology and End Results database).
Is prostate biopsy typically used in combination with any other treatments?
It seems that a biopsy is normally the most routinely used modality in conjunction with other treatments in patients with [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer). In the cases of patients in whom the prostate cancer is found at the same time as any other disease, or after a prior treatment of another type of cancer (cancer survivors), or in a patient with high risk for prostate cancer (such as patient with PSA of 10 ng/ml), an additional biopsy is advisable. Even in the majority of cases, in most cases biopsy is performed as the first and definitive treatment of prostate cancer. Additional treatments, and therefore an additional biopsy in the majority of cases, are needed to clarify diagnosis in the following circumstances:\n1.
What is the primary cause of prostate cancer?
The most common cause of all [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer)s is carcinoma in situ. This tumor form is the precursor of all prostate cancer and it is the most likely to be cured with curative treatment. The second most common carcinoma in situ is extracapsular cancer which is more or less always lethal. The third most common tumor form, extracapsular perineal cancer, is responsible for more than half of all prostate cancers, but is also rarely lethal. Of all prostate cancers, only a small number is caused by carcinoma in situ. Of the extracapsular carcinomas only a few can be cured with curative treatment. Extracapsular cancers cause about half of prostate cancers.
How quickly does prostate cancer spread?
The majority of men with [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) have no disease or only cancer localized to the prostate. Because prostate cancer and BPH may require surveillance, a question is, how often does the disease disseminate within 5 years? answer: In a recent study, findings is the first to systematically relate the prevalence of metastases and prostate cancer stage using the seminal pathology report, the data set derived from pre-treatment clinical evaluations performed by urologists and urologic oncologists, and imaging data obtained from diagnostic imaging investigations performed by radiology departments. The study provided reliable and comprehensive information about dissemination and clinical outcome of prostate cancer.
What is the latest research for prostate cancer?
Prostate cancer seems to have become one of the most feared and most feared diseases since the inception of prostate specific antigen (PSA) testing for early detection of prostate cancer in 1989. There have been numerous reports pointing to the importance of detecting and treating early stage prostate cancer. The current understanding of the molecular markers for prostate cancer detection has greatly improved.
How serious can prostate cancer be?
The seriousness of the disease can vary in different patients. Recent findings of PSA tests should be interpreted in the context of individual patient characteristics and risks of prostate cancer. The risks in different groups of patients are as follows (for more detailed analyses see: http://www.prostatehelp.org/ProstateHealth/prostate-cancer/pca/risk.php):\n- PSA Level <10ng/mL, age ≤ 65 years old has a negligible risk of disease.\n- PSA Level between 10 to 20ng/mL, age between 45 to 69 years old is associated with a 1% risk.